NCT02390297View on ClinicalTrials.gov

Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients

Active, not recruitingOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 31, 2031

Study Completion Date

October 31, 2031

Conditions
HIV-1 InfectionReceipt of Cal-1 Modified Hematopoietic Cellular Products
Interventions
GENETIC

Blood tests

Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses

Trial Locations (2)

90035

UCLA CARE Center, Los Angeles

94115

Quest Clinical Research, San Francisco

Sponsors

Lead Sponsor

Calimmune, Inc.
All Listed Sponsors
lead

Calimmune, Inc.

INDUSTRY